Starting semaglutide at a higher dose: what the licensed schedule actually allows

You've been told the starting dose is low, and you're wondering why

It's a question our prescribers hear most weeks: if the effective dose is 2.4 mg, why start at 0.25 mg and wait months to get there? The short answer is that semaglutide slows gastric emptying and alters appetite signalling, mechanisms that are powerful but that the gut needs to adapt to gradually. Beginning at a fraction of the maintenance dose gives your digestive system time to settle, reducing the nausea, vomiting and reflux that make some people want to stop treatment in the first few weeks.

Clinical trials ran this phased schedule deliberately. The STEP 1 trial, published in the New England Journal of Medicine, saw participants reach 2.4 mg through a stepwise titration, and it was at that maintenance dose that an average body-weight reduction of around 15% was observed over 68 weeks. There is no shortcut in that data. Starting higher did not feature as a tested protocol because the tolerability rationale for the gradual approach is well established.

The NHS semaglutide medicines page sets out the approved schedule clearly: 0.25 mg for weeks one to four, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, with each step held for roughly four weeks. That progression is what the medicine's licence is built around. Prescribers follow it because the evidence behind it is solid, not because the rules are arbitrary.

Situations where a prescriber might not start you at 0.25 mg

The licensed schedule is the default, but clinical care is rarely one-size-fits-all. There are specific circumstances in which a prescriber may consider a different starting point, and they are narrower than most people expect.

If you are transferring from another semaglutide product, or restarting Wegovy after a period on the medicine, a prescriber will look at how long you were off treatment and what dose you reached. A short gap may mean resuming closer to where you left off rather than going back to the very beginning. This is documented in the product's prescribing information and is something a prescriber assesses individually, not something a patient decides unilaterally.

What does not apply here is the idea of simply requesting a higher starting dose because you want faster results. There is no clinical basis for that, and no prescriber operating within their duty of care would agree to it. The question of starting on a higher Wegovy dose deserves a direct answer, and that answer is: not under the standard licence, and not without a specific clinical reason reviewed by a prescriber. If you've read elsewhere that some clinics will start you at 0.5 mg or above, that represents a departure from the licensed schedule, one that warrants very careful scrutiny.

What the full dose range now looks like for semaglutide

Semaglutide's approved dose range expanded significantly in 2026. The MHRA approved a 7.2 mg maintenance dose, first as three 2.4 mg pens used weekly, then as a dedicated single-dose 7.2 mg pen approved in April 2026. Trials at this higher dose reported an average weight loss of around 20.7% over 72 weeks, bringing results closer to those seen with tirzepatide at its highest strength.

The 7.2 mg dose is licensed for adults with a BMI of 30 or above, and it is still reached by titrating up through the standard schedule, not by beginning at a high dose. The starting point remains 0.25 mg regardless of which maintenance dose you and your prescriber are aiming for. You can read more about what the full range covers on the Wegovy dose guide, or explore the broader question of the highest dose of semaglutide available.

It is also worth knowing that semaglutide comes in different licensed products: Wegovy for weight management, and Ozempic for type 2 diabetes. They are not interchangeable for prescribing purposes, and Ozempic is not licensed for weight loss in the UK. If you've been reading about starting doses across different products, make sure the information you're looking at is specific to Wegovy. The starting dose for semaglutide varies by indication, and conflating the two products is a common source of confusion.

What this means in practice if you're considering treatment

For most people starting Wegovy for weight management, the journey begins at 0.25 mg, full stop. The four-week steps feel slow, especially when the results you've read about were achieved at 2.4 mg or higher. But side effects are more manageable when the dose climbs gradually, and people who tolerate the early weeks well tend to stay on treatment long enough to see meaningful results.

If you are coming from another clinic or provider, a prescriber at a regulated service will want to see evidence of your current dose and treatment history before deciding where to begin. That is a patient-safety measure, not bureaucracy. Understanding what the higher dose of semaglutide actually involves (and the clinical steps needed to reach it) is a more useful frame than asking whether you can skip ahead.

Cost is a reasonable part of the picture too. Because the early dose levels require fewer milligrams per pen, understanding how the cost of Wegovy treatment maps across the schedule can help you plan. And if you'd like to understand the full treatment landscape before making a decision, a read through the Wegovy overview is a good place to ground yourself.

When you're ready to talk through your individual situation with a prescriber, checking your eligibility with nume is the natural next step. Every consultation is reviewed the same day by a GPhC-registered Independent Prescriber (a real clinician reading your answers) with no waiting list and no subscription commitment.